The DOI matches its Crossref record.
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial
Abstract
We report a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB) in 372 ambulatory patients with relapsing-remitting multiple sclerosis (MS). Entry criteria included an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 and at least two exacerbations in the previous 2 years. One-third of the patients received placebo, one-third 1.6 million international units (MIU) of IFNB, and one-third 8 MIU of IFNB, self-administered by subcutaneous injections every other day. The primary end points were differences in exacerbation rates and proportion of patients remaining exacerbation-free. The annual exacerbation rate for patients receiving placebo was 1.27; for 1.6 MIU IFNB, 1.17; and for 8 MIU IFNB, 0.84 after 2 years. Exacerbation rates were significantly lower in both treatment groups compared with the placebo group (8 MIU versus placebo, p = 0.0001; 1.6 MIU versus placebo, p = 0.0101; and 8 MIU versus 1.6 MIU, p = 0.0086), suggesting a dosage effect. The reduction in exacerbation severity in the 8 MIU group was attributable to a twofold reduction in the frequency of moderate and severe attacks. More patients in the 8 MIU group (n = 36) were exacerbation-free at 2 years compared with the placebo group (n = 18; p = 0.007). EDSS scores changed little from baseline in both the placebo and treatment arms. Accordingly, a significant change in disability could not be discerned in this trial. Finally, in serial MRIs, MS activity was significantly less in the high-dose IFNB group.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
Confavreux, C., Hutchinson, M., Hours, M. M., Cortinovis-Tourniaire, P., & Moreau, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390501 · Cited by 1,559
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Interferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,017
Self-citationImmunomodulatory functions of type I interferons
González-Navajas, J. M., Lee, J., David, M., & Raz, E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3133 · Cited by 1,011
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Weinshenker, B. G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N., & Rodriguez, M. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q · Cited by 894
Sommereyns, C., Paul, S., Staeheli, P., & Michiels, T. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000017 · Cited by 772
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L., & the Multiple Sclerosis Collaborative Research Group (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
Self-citationECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 712
Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
Meyer-Moock, S., Feng, Y.-S., Maeurer, M., Dippel, F.-W., & Kohlmann, T. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-58 · Cited by 639
Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Environmental factors and multiple sclerosis
Ebers, G. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70042-5 · Cited by 629
Beck, R. W., Cleary, P. A., Trobe, J. D., Kaufman, D. I., Kupersmith, M. J., Paty, D. W., & Brown, C. H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312093292403 · Cited by 579
PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, & the University of British Columbia MS/MRI Analysis Group (2001) · Neurology · doi:10.1212/wnl.56.12.1628 · Cited by 571
Self-citationDurelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A., Montanari, E., & Zaffaroni, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08430-1 · Cited by 547
Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Trojano, M., Lugaresi, A., et al. (2019) · JAMA · doi:10.1001/jama.2018.20588 · Cited by 546
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Mikol, D. D., Barkhof, F., Chang, P., Coyle, P. K., Jeffery, D. R., Schwid, S. R., Stubinski, B., & Uitdehaag, B. M. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70200-x · Cited by 486
Kappos, L., Gold, R., Miller, D. H., MacManus, D. G., Havrdova, E., Limmroth, V., Polman, C. H., Schmierer, K., Yousry, T. A., Yang, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61619-0 · Cited by 482
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 471
Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Miller, D. H., Albert, P. S., Barkhof, F., Francis, G., Frank, J. A., Hodgkinson, S., Lublin, F. D., Paty, D. W., Reingold, S. C., & Simon, J. (1996) · Annals of Neurology · doi:10.1002/ana.410390104 · Cited by 444
Edan, G., Miller, D., Clanet, M., Confavreux, C., Lyon-Caen, O., Lubetzki, C., Brochet, B., Berry, I., Rolland, Y., Froment, J. C., et al. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.2.112 · Cited by 425
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
Effect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Kappos, L., Bates, D., Hartung, H.-P., Havrdova, E., Miller, D., Polman, C. H., Ravnborg, M., Hauser, S. L., Rudick, R. A., Weiner, H. L., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70078-9 · Cited by 421
Natural history of multiple sclerosis
Weinshenker, B. G. (1994) · Annals of Neurology · doi:10.1002/ana.410360704 · Cited by 405
O'Connor, P., Filippi, M., Arnason, B., Comi, G., Cook, S., Goodin, D., Hartung, H.-P., Jeffery, D., Kappos, L., Boateng, F., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70226-1 · Cited by 405
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70068-7 · Cited by 398
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions
Banwell, B., Ghezzi, A., Bar-Or, A., Mikaeloff, Y., & Tardieu, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70242-9 · Cited by 394
Sorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14541-2 · Cited by 383
Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S., Nahler, G., & Mamoli, B. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09377-4 · Cited by 381
Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis
Martin, R., McFarland, H. F., & Boggs, J. M. (1995) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408369509084683 · Cited by 376
Risk factors for and management of cognitive dysfunction in multiple sclerosis
Benedict, R. H. B., & Zivadinov, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.61 · Cited by 370
Stüve, O., Dooley, N. P., Uhm, J. H., Antel, J. P., Francis, G. S., Yong, V. W., & Williams, G. (1996) · Annals of Neurology · doi:10.1002/ana.410400607 · Cited by 348
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
Sommer, N., Löschmann, P.-A., Northoff, G. H., Weller, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Riethmüller, A., Fontana, A., et al. (1995) · Nature Medicine · doi:10.1038/nm0395-244 · Cited by 345
Treatment of multiple sclerosis — success from bench to bedside
Tintore, M., Vidal-Jordana, A., & Sastre-Garriga, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 343
Multiple sclerosis—a quiet revolution
Ransohoff, R. M., Hafler, D. A., & Lucchinetti, C. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.14 · Cited by 338
Multiple sclerosis and depression
Feinstein, A. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511417835 · Cited by 337
Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients
Río, J., Nos, C., Tintoré, M., Téllez, N., Galán, I., Pelayo, R., Comabella, M., & Montalban, X. (2006) · Annals of Neurology · doi:10.1002/ana.20740 · Cited by 327
Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
Rice, G. P. A., Filippi, M., Comi, G., & for the Cladribine Clinical Study Group and for the Cladribine MRI Study Group* (2000) · Neurology · doi:10.1212/wnl.54.5.1145 · Cited by 325
Keegan, B. M., & Noseworthy, J. H. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103909 · Cited by 319
The Natural History of Multiple Sclerosis
Weinshenker, B. G. (1995) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30064-1 · Cited by 313
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
Kieseier, B. C. (2011) · CNS Drugs · doi:10.2165/11591110-000000000-00000 · Cited by 308
Evolving concepts in the treatment of relapsing multiple sclerosis
Comi, G., Radaelli, M., & Soelberg Sørensen, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32388-1 · Cited by 306
Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., & Goelz, S. E. (1998) · Pharmaceutical Research · doi:10.1023/a:1011974512425 · Cited by 304
Goodkin, D. E., Rudick, R. A., Medendorp, S. V., Daughtry, M. M., Schwetz, K. M., Fischer, J., & van Dyke, C. (1995) · Annals of Neurology · doi:10.1002/ana.410370108 · Cited by 304
Multiple sclerosis: Side effects of interferon beta therapy and their management
Walther, E. U., & Hohlfeld, R. (1999) · Neurology · doi:10.1212/wnl.53.8.1622 · Cited by 304
Interferons in relapsing remitting multiple sclerosis: a systematic review
Filippini, G., Munari, L., Incorvaia, B., Ebers, G. C., Polman, C., D'Amico, R., & Rice, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12512-3 · Cited by 302
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
Can the immune system be harnessed to repair the CNS?
Popovich, P. G., & Longbrake, E. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2398 · Cited by 284
Baseline MRI predicts future attacks and disability in clinically isolated syndromes
Tintoré, M., Rovira, A., Río, J., Nos, C., Grivé, E., Téllez, N., Pelayo, R., Comabella, M., Sastre-Garriga, J., & Montalban, X. (2006) · Neurology · doi:10.1212/01.wnl.0000237354.10144.ec · Cited by 282
MULTIPLE SCLEROSIS AND THE UROLOGIST
LITWILLER, S. E., FROHMAN, E. M., & ZIMMERN, P. E. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61760-9 · Cited by 282
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed
Feinstein, A., Freeman, J., & Lo, A. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70231-5 · Cited by 281
Disease‐modifying treatments for multiple sclerosis – a review of approved medications
Torkildsen, Ø., Myhr, K. ‐., & Bø, L. (2016) · European Journal of Neurology · doi:10.1111/ene.12883 · Cited by 280
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Sormani, M. P., & Bruzzi, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70103-0 · Cited by 278
Progress in determining the causes and treatment of multiple sclerosis
Noseworthy, J. H. (1999) · Nature · doi:10.1038/399a040 · Cited by 278
Comi, G., Pulizzi, A., Rovaris, M., Abramsky, O., Arbizu, T., Boiko, A., Gold, R., Havrdova, E., Komoly, S., Selmaj, K., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60918-6 · Cited by 278
Influence of infection on exacerbations of multiple sclerosis
Panitch, H. S. (1994) · Annals of Neurology · doi:10.1002/ana.410360709 · Cited by 276
The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
Minden, S. L., Frankel, D., Hadden, L., Perloff, J., Srinath, K. P., & Hoaglin, D. C. (2006) · Multiple Sclerosis Journal · doi:10.1191/135248506ms1262oa · Cited by 272
New natural history of interferon‐β–treated relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21102 · Cited by 270
De Jager, P. L., Chibnik, L. B., Cui, J., Reischl, J., Lehr, S., Simon, K. C., Aubin, C., Bauer, D., Heubach, J. F., Sandbrink, R., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70275-3 · Cited by 266
Vartanian, T., Li, Y., Zhao, M., & Stefansson, K. (1995) · Molecular Medicine · doi:10.1007/bf03401888 · Cited by 261
Villar, L. M., Sádaba, M. C., Roldán, E., Masjuan, J., González-Porqué, P., Villarrubia, N., Espiño, M., García-Trujillo, J. A., Bootello, A., & Álvarez-Cermeño, J. C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522833 · Cited by 259
Factors that influence adherence with disease-modifying therapy in MS
Treadaway, K., Cutter, G., Salter, A., Lynch, S., Simsarian, J., Corboy, J., Jeffery, D., Cohen, B., Mankowski, K., Guarnaccia, J., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0096-y · Cited by 258
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 256
Immunopathogenesis and immunotherapy of multiple sclerosis
Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., & Hartung, H.-P. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0154 · Cited by 254
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy
Ioannou, Y., & Isenberg, D. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200007)43:7<1431::aid-anr3>3.0.co;2-e · Cited by 252
Health‐related quality of life in multiple sclerosis: effects of natalizumab
Rudick, R. A., Miller, D., Hass, S., Hutchinson, M., Calabresi, P. A., Confavreux, C., Galetta, S. L., Giovannoni, G., Havrdova, E., Kappos, L., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21163 · Cited by 195
Mathur, V., Burai, R., Vest, R. T., Bonanno, L. N., Lehallier, B., Zardeneta, M. E., Mistry, K. N., Do, D., Marsh, S. E., Abud, E. M., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.032 · Cited by 175
Epidemiology and natural history of multiple sclerosis: new insights
Kantarci, O., & Wingerchuk, D. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000227033.47458.82 · Cited by 156
Mohr, D. C., Goodkin, D. E., Likosk, W., Gatto, N., Neilley, L. K., Griffin, C., & Stiebling, B. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600200502 · Cited by 131
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Stüve, O., & Bennett, J. L. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00003.x · Cited by 123
Zivadinov, R., Zorzon, M., Tommasi, M. A., Nasuelli, D., Bernardi, M., Monti-Bragadin, L., & Cazzato, G. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00225-9 · Cited by 81
Interferon γ- and interleukin-4-secreting cells in multiple sclerosis
Lu, C.-Z., Jensen, M. A., & Arnason, B. G. W. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90241-p · Cited by 77
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328122de1b · Cited by 46
Palace, J., Duddy, M., Lawton, M., Bregenzer, T., Zhu, F., Boggild, M., Piske, B., Robertson, N. P., Oger, J., Tremlett, H., et al. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318360 · Cited by 44
Interferon-β1bin multiple sclerosis
Buttmann, M., & Rieckmann, P. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.3.227 · Cited by 43
Tilling, K., Lawton, M., Robertson, N., Tremlett, H., Zhu, F., Harding, K., Oger, J., & Ben-Shlomo, Y. (2016) · Health Technology Assessment · doi:10.3310/hta20810 · Cited by 43
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38
Metadata
- Authors
- The IFNB Multiple Sclerosis Study Group
- Venue
- Neurology
- Published
- 1993-04
- Volume
- 43
- Issue
- 4
- Pages
- 655-655
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4210548604
- Cited by
- 2,085
- References
- 0
- FWCI
- 51.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.